Evidence map›Paper›PMID 36169100›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022

Large Oncosome-Loaded VAPA Promotes Bone-Tropic Metastasis of Hepatocellular Carcinoma Via Formation of Osteoclastic Pre-Metastatic Niche.

Shuxia Zhang, Xinyi Liao, Suwen Chen, Wanying Qian, Man Li, Yingru Xu, Meisongzhu Yang, Xincheng Li, Shuang Mo, Miaoling Tang and 7 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Osteoblast-Derived ECM1 Promotes Anti-Androgen Resistance in Bone Metastatic Prostate Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  17. Multi-stage mechanisms of tumor metastasis and therapeutic strategies.Signal transduction and targeted therapy · 2024
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Shuxia ZhangProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Xinyi LiaoProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Suwen ChenProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Wanying QianProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Man LiProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Yingru XuProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Meisongzhu YangProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Xincheng LiProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Shuang MoProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Miaoling TangProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Xingui WuProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Yameng HuProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Ziwen LiProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Ruyuan YuProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Ainiwaerjiang AbudourousuliProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.
Libing SongState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510080, P. R. China.
Jun LiProgram of Cancer Research, Key Laboratory of Protein Modification and Degradation and Guangzhou Institute of Oncology, Affiliated Guangzhou Women and Children's Hospital, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 510623, P. R. China.ORCID 0000-0003-0572-1344
Sun Yat-sen University · CN

Funding

China Postdoctoral Science Foundation 2022M713622National Key Research and Development Program of China 2020YFA0509400Natural Science Foundation of China 81621004Natural Science Foundation of China 81830082Natural Science Foundation of China 82030078Natural Science Foundation of China 82072609
6 · The paper itself

Abstract

Tumor-derived extracellular vesicles (EVs) function as critical mediators in selective modulation of the microenvironment of distant organs to generate a pre-metastatic niche that facilitates organotropic metastasis. Identifying the organ-specific molecular determinants of EVs can develop potential anti-metastatic therapeutic targets. In the current study, large oncosomes (LOs), atypically large cancer-derived EVs, are found to play a crucial role in facilitating bone-tropic metastasis of hepatocellular carcinoma (HCC) cells by engineering an osteoclastic pre-metastatic niche and establishing a vicious cycle between the osteoclasts and HCC cells. Transmembrane protein, VAMP-associated protein A (VAPA), is significantly enriched on LOs surface via direct interaction with LOs marker αV-integrin. VAPA-enriched LOs-induced pre-metastatic education transforms the bone into a fertile milieu, which supports the growth of metastatic HCC cells. Mechanically, LOs-delivered VAPA integrates to plasma membrane of osteoclasts and directly interacts with and activates neural Wiskott-Aldrich syndrome protein (N-WASP) via dual mechanisms, consequently resulting in ARP2/3 complex-mediated reorganization of actin cytoskeleton in osteoclasts and osteoclastogenesis. Importantly, treatment with N-WASP inhibitor 187-1-packaged LOs (LOs/187-1) dramatically abolishes the inductive effect of VAPA-enriched LOs on pre-metastatic niche formation and precludes HCC bone metastasis. These findings reveal a plausible mechanism for bone-tropism of HCC and can represent a potential strategy to prevent HCC bone metastasis.

Indexed as

Bone NeoplasmsCarcinoma, HepatocellularLiver NeoplasmsHumansOsteoclastsSignal TransductionStaphylococcal Protein ATumor MicroenvironmentStaphylococcal Protein Abone metastasishepatocellular carcinomaosteoclastic pre-metastatic nicheVAMP-associated protein A (VAPA)

Identifiers

PMID36169100
PMCPMC9631052
OpenAlexW4297488931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.